BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borah P, Deb PK, Chandrasekaran B, Goyal M, Bansal M, Hussain S, Shinu P, Venugopala KN, Al-Shar'i NA, Deka S, Singh V. Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. Front Mol Biosci 2021;8:627723. [PMID: 33681293 DOI: 10.3389/fmolb.2021.627723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 El-malah AA, Gineinah MM, Deb PK, Khayyat AN, Bansal M, Venugopala KN, Aljahdali AS. Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing. Pharmaceuticals 2022;15:827. [DOI: 10.3390/ph15070827] [Reference Citation Analysis]
2 Chandrasekaran B, Saravanan M. Editorial: Pharmacological and Biochemical Perspectives of Kinase Inhibitors in Cancer and COVID-19 Therapeutics, Volume I. Front Pharmacol 2022;13:916324. [DOI: 10.3389/fphar.2022.916324] [Reference Citation Analysis]
3 Pagliano P, Sellitto C, Scarpati G, Ascione T, Conti V, Franci G, Piazza O, Filippelli A. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). Expert Opin Drug Discov 2021;:1-10. [PMID: 34412564 DOI: 10.1080/17460441.2021.1970743] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bezbaruah R, Borah P, Kakoti BB, Al-Shar'I NA, Chandrasekaran B, Jaradat DMM, Al-Zeer MA, Abu-Romman S. Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19. Front Mol Biosci 2021;8:635337. [PMID: 33937326 DOI: 10.3389/fmolb.2021.635337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Finsterer J, Scorza FA. Mental compromise in SARS-CoV-2 infected patients is multicausal, organic or inorganic. Brain Commun 2021;3:fcab218. [PMID: 34557670 DOI: 10.1093/braincomms/fcab218] [Reference Citation Analysis]
6 Kumar A, Chattopadhyay A, Gupta S. Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implications. Asian J Psychiatr 2022;73:103101. [PMID: 35461033 DOI: 10.1016/j.ajp.2022.103101] [Reference Citation Analysis]
7 Patel N, Dahman B, Bajaj JS. Development of New Mental and Physical Health Sequelae among US Veterans after COVID-19. J Clin Med 2022;11:3390. [PMID: 35743461 DOI: 10.3390/jcm11123390] [Reference Citation Analysis]
8 Belopasov VV, Zhuravleva EN, Nugmanova NP, Abdrashitova AT. Post-covid-19 neurological syndromes. Journal of Clinical Practice 2021;12:69-82. [DOI: 10.17816/clinpract71137] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Molina JD, Rodrigo Holgado I, Juanes González A, Combarro Ripoll CE, Lora Pablos D, Rubio G, Alonso J, Rivas-clemente FPJ. Neuropsychological Symptom Identification and Classification in the Hospitalized COVID-19 Patients During the First Wave of the Pandemic in a Front-Line Spanish Tertiary Hospital. Front Psychiatry 2022;13:838239. [DOI: 10.3389/fpsyt.2022.838239] [Reference Citation Analysis]